-
Howe trusts Tonali will not follow Isak lead out of Newcastle
-
Vonn to provide injury update as Milan-Cortina Olympics near
-
France summons Musk for 'voluntary interview', raids X offices
-
US judge to hear request for 'immediate takedown' of Epstein files
-
Russia resumes large-scale strikes on Ukraine in glacial temperatures
-
Fit-again France captain Dupont partners Jalibert against Ireland
-
French summons Musk for 'voluntary interview' as authorities raid X offices
-
IOC chief Coventry calls for focus on sport, not politics
-
McNeil's partner hits out at 'brutal' football industry after Palace move collapses
-
Proud moment as Prendergast brothers picked to start for Ireland
-
Germany has highest share of older workers in EU
-
Teen swims four hours to save family lost at sea off Australia
-
Ethiopia denies Trump claim mega-dam was financed by US
-
Russia resumes strikes on freezing Ukrainian capital ahead of talks
-
Malaysian court acquits French man on drug charges
-
Switch 2 sales boost Nintendo results but chip shortage looms
-
From rations to G20's doorstep: Poland savours economic 'miracle'
-
Russia resumes strikes on freezing Ukrainian capital
-
'Way too far': Latino Trump voters shocked by Minneapolis crackdown
-
England and Brook seek redemption at T20 World Cup
-
Coach Gambhir under pressure as India aim for back-to-back T20 triumphs
-
'Helmets off': NFL stars open up as Super Bowl circus begins
-
Japan coach Jones says 'fair' World Cup schedule helps small teams
-
Do not write Ireland off as a rugby force, says ex-prop Ross
-
Winter Olympics 2026: AFP guide to Alpine Skiing races
-
Winter Olympics to showcase Italian venues and global tensions
-
Buoyant England eager to end Franco-Irish grip on Six Nations
-
China to ban hidden car door handles in industry shift
-
Sengun leads Rockets past Pacers, Ball leads Hornets fightback
-
Waymo raises $16 bn to fuel global robotaxi expansion
-
Netflix to livestream BTS comeback concert in K-pop mega event
-
Rural India powers global AI models
-
Equities, metals, oil rebound after Asia-wide rout
-
Bencic, Svitolina make history as mothers inside tennis top 10
-
Italy's spread-out Olympics face transport challenge
-
Son of Norway crown princess stands trial for multiple rapes
-
Side hustle: Part-time refs take charge of Super Bowl
-
Paying for a selfie: Rome starts charging for Trevi Fountain
-
Faced with Trump, Pope Leo opts for indirect diplomacy
-
NFL chief expects Bad Bunny to unite Super Bowl audience
-
Australia's Hazlewood to miss start of T20 World Cup
-
Bill, Hillary Clinton to testify in US House Epstein probe
-
Cuba confirms 'communications' with US, but says no negotiations yet
-
From 'watch his ass' to White House talks for Trump and Petro
-
Trump says not 'ripping' down Kennedy Center -- much
-
Sunderland rout 'childish' Burnley
-
Musk merges xAI into SpaceX in bid to build space data centers
-
Former France striker Benzema switches Saudi clubs
-
Sunderland rout hapless Burnley
-
Costa Rican president-elect looks to Bukele for help against crime
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
O.Gaspar--PC